Trial Profile
A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Subjects with Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Glipizide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ENDURE
- Sponsors Takeda; Takeda Global Research and Development Center
- 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (End Date: 17 Oct 2012).
- 01 Dec 2016 Results from economic analysis assessing the relationship between increased glycemic durability and cost-effectiveness of alogliptin published in the Diabetes Therapy.
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.